106 related articles for article (PubMed ID: 1412158)
1. Insights on monoclonal antibodies to kininogens' heavy chain which influence kininogens' binding to platelets.
Jiang Y; Nawarawong W; Meloni FJ; Schmaier AH
Thromb Haemost; 1992 Aug; 68(2):143-8. PubMed ID: 1412158
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies.
Sugi T; Mclntyre JA
Thromb Haemost; 1996 Sep; 76(3):354-60. PubMed ID: 8883270
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cell binding and thrombin inhibitory regions on kininogens' heavy chain.
Jiang YP; Schmaier AH
Agents Actions Suppl; 1992; 38 ( Pt 1)():233-40. PubMed ID: 1466275
[TBL] [Abstract][Full Text] [Related]
4. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets.
Jiang YP; Muller-Esterl W; Schmaier AH
J Biol Chem; 1992 Feb; 267(6):3712-7. PubMed ID: 1740422
[TBL] [Abstract][Full Text] [Related]
5. High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage.
Meloni FJ; Gustafson EJ; Schmaier AH
Blood; 1992 Mar; 79(5):1233-44. PubMed ID: 1536948
[TBL] [Abstract][Full Text] [Related]
6. Production and characterization of monoclonal antibodies directed against high and low molecular weight kininogens.
Hentges F; Kohnen M; Grigioni F; Reichert P; Humbel R; Schneider F
Bull Soc Sci Med Grand Duche Luxemb; 1994; 131(2):9-17. PubMed ID: 7820912
[TBL] [Abstract][Full Text] [Related]
7. Expression of thrombospondin 1 on the surface of activated platelets mediates their interaction with the heavy chains of human kininogens through Lys 244-Pro 254.
DeLa Cadena RA; Kunapuli SP; Walz DA; Colman RW
Thromb Haemost; 1998 Jan; 79(1):186-94. PubMed ID: 9459346
[TBL] [Abstract][Full Text] [Related]
8. Platelet thrombospondin interactions with human high and low molecular weight kininogens.
DeLa Cadena RA; Wyshock EG; Kunapuli SP; Schultze RL; Miller M; Walz DA; Colman RW
Thromb Haemost; 1994 Jul; 72(1):125-31. PubMed ID: 7974360
[TBL] [Abstract][Full Text] [Related]
9. Conformational changes in low molecular weight kininogen alters its ability to bind to endothelial cells.
Hasan AA; Zhang J; Samuel M; Schmaier AH
Thromb Haemost; 1995 Oct; 74(4):1088-95. PubMed ID: 8560418
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation.
Meloni FJ; Schmaier AH
J Biol Chem; 1991 Apr; 266(11):6786-94. PubMed ID: 2016293
[TBL] [Abstract][Full Text] [Related]
11. Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains.
Schmaier AH; Schutsky D; Farber A; Silver LD; Bradford HN; Colman RW
J Biol Chem; 1987 Jan; 262(3):1405-11. PubMed ID: 2433279
[TBL] [Abstract][Full Text] [Related]
12. Mapping of functional domains of human high molecular weight and low molecular weight kininogens using murine monoclonal antibodies.
Ishiguro H; Higashiyama S; Ohkubo I; Sasaki M
Biochemistry; 1987 Nov; 26(22):7021-9. PubMed ID: 2447941
[TBL] [Abstract][Full Text] [Related]
13. Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens.
Sugi T; McIntyre JA
J Autoimmun; 2001 Nov; 17(3):207-14. PubMed ID: 11712858
[TBL] [Abstract][Full Text] [Related]
14. Immunological characterization of rat kininogens with monoclonal antibodies to T-kininogen. Distinction between the different domains of T-kininogen and the multiple rat kininogens.
Lesage S; Bouhnik J; Richoux JP; Baussant T; Gauthier F; Eager K; Corvol P; Alhenc-Gelas F
Eur J Biochem; 1992 Mar; 204(2):501-8. PubMed ID: 1541265
[TBL] [Abstract][Full Text] [Related]
15. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface.
DeLa Cadena RA; Colman RW
Protein Sci; 1992 Jan; 1(1):151-60. PubMed ID: 1304876
[TBL] [Abstract][Full Text] [Related]
16. Comparison of properties of monoclonal and polyclonal antibodies against the light chain of human high molecular weight kininogen.
Kleniewski J; Dingle S; Donaldson VH
J Lab Clin Med; 1988 Jan; 111(1):93-103. PubMed ID: 2447215
[TBL] [Abstract][Full Text] [Related]
17. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5).
Wachtfogel YT; DeLa Cadena RA; Kunapuli SP; Rick L; Miller M; Schultze RL; Altieri DC; Edgington TS; Colman RW
J Biol Chem; 1994 Jul; 269(30):19307-12. PubMed ID: 8034694
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of inhibition of platelet calpain II by human kininogens.
Bradford HN; Schmaier AH; Colman RW
Biochem J; 1990 Aug; 270(1):83-90. PubMed ID: 2396995
[TBL] [Abstract][Full Text] [Related]
19. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain.
Hasan AA; Cines DB; Zhang J; Schmaier AH
J Biol Chem; 1994 Dec; 269(50):31822-30. PubMed ID: 7989355
[TBL] [Abstract][Full Text] [Related]
20. Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain.
Bradford HN; Jameson BA; Adam AA; Wassell RP; Colman RW
J Biol Chem; 1993 Dec; 268(35):26546-51. PubMed ID: 8253784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
